Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

FLEX PHARMA INC (FLKS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
5.49(c) 5.46(c) 5.47(c) 5.18(c) 5.29(c) Last
14 263 24 565 30 017 95 649 19 259 Volume
+0.73% -0.55% +0.18% -5.30% +2.12% Change
More quotes
Financials (USD)
Sales 2018 1,26 M
EBIT 2018 -38,6 M
Net income 2018 -38,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 7,09 M
EBIT 2019 -44,0 M
Net income 2019 -43,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 74,2x
Capi. / Sales2019 13,1x
Capitalization 93,1 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
04/19FLEX PHARMA : Patent Issued for Methods and Compositions for Preventing and Reli..
AQ
03/29FLEX PHARMA : Reports Positive Topline Data from Exploratory Phase 2 Trial of FL..
AQ
03/26FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Other Events
AQ
03/26FLEX PHARMA, INC. : Other Events (form 8-K)
AQ
03/26FLEX PHARMA : Reports Positive Topline Data from Exploratory Phase 2 Trial of FL..
BU
03/16FLEX PHARMA INC : Today’s Research Reports on Stocks to Watch: Flex Pharma, Inc...
AC
03/15FLEX PHARMA : Reports Year End 2017 Financial Results
AQ
03/12FLEX PHARMA : Reports Year End 2017 Financial Results
AQ
03/07FLEX PHARMA : Management's Discussion and Analysis of Financial Condition and Re..
AQ
03/07FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financia..
AQ
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/19Flex Pharma $FLKS Earns News Sentiment Score of 0.28  
04/18-$0.50 EPS Expected for Flex Pharma Inc $FLKS This Quarter  
04/18Flex Pharma upgraded by Zacks Investment Research to buy. $6.00 PT.  
04/16Flex Pharma Inc $FLKS Receives Average Rating of “Hold” from Brokerages  
04/04Get the latest ratings for $OIBR $FLKS $ENTL $CKPT $BBU in your inbox with Ma.. 
More tweets
Qtime:48
News from SeekingAlpha
03/28Midday Gainers / Losers (3/28/2018) 
03/28HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (03/28/2018) 
03/27YOUR DAILY PHARMA SCOOP : Flex Pharma Data, Protagonist Setback, ImmunoGen Resul.. 
03/26Flex Pharma's FLX-787 shows treatment effect in MS patients with cramps/spasm.. 
03/19Midday Gainers / Losers (3/19/2018) 
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 17,0 $
Spread / Average Target 221%
EPS Revisions
Managers
NameTitle
William K. McVicar President, Chief Executive Officer & Director
Christoph H. Westphal Chairman
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
Peter Barton Hutt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC48.42%93
GILEAD SCIENCES3.31%96 094
VERTEX PHARMACEUTICALS5.89%40 153
REGENERON PHARMACEUTICALS-15.95%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998